Related Experiment Video
Updated: May 17, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Prothrombotic disorders in abdominal vein thrombosis
F W G Leebeek1, J H Smalberg, H L A Janssen
1Department of Haematology, Erasmus University Medical Center, Rotterdam, the Netherlands. f.leebeek@erasmusmc.nl
Abdominal vein thrombosis, a serious condition, often stems from multiple inherited and acquired risk factors. Early anticoagulant treatment is crucial due to high recurrence rates, though treatment duration requires careful consideration of bleeding risks.
Area of Science:
- Hematology
- Vascular Medicine
- Thrombosis Research
Background:
- Abdominal vein thrombosis (AVT) is a rare but life-threatening condition, primarily affecting hepatic (Budd-Chiari syndrome, BCS), portal (PVT), and mesenteric veins.
- Multiple inherited and acquired thrombophilia factors are common in AVT patients, with specific genetic variants linked to BCS and PVT.
- Myeloproliferative neoplasms (MPNs) are identified as underlying disorders in a significant portion of AVT cases.
Purpose of the Study:
- To review recent large-scale studies on the etiological factors of abdominal vein thrombosis.
- To discuss newly reported risk factors and the multifactorial nature of BCS and PVT.
- To highlight the necessity of immediate anticoagulant treatment and the ongoing debate regarding its duration.
Main Methods:
- Review of recent large-scale studies and reported risk factors for abdominal vein thrombosis.
- Analysis of etiological factors, including inherited thrombophilia, acquired conditions, and myeloproliferative neoplasms.
- Discussion of treatment strategies, focusing on anticoagulant therapy and bleeding risk assessment.
Main Results:
- AVT is frequently multifactorial, with many patients presenting with two or more prothrombotic risk factors.
- Specific genetic factors like Factor V Leiden are associated with BCS, while prothrombin gene variants are more common in PVT.
- Myeloproliferative neoplasms (MPNs) are underlying causes in 30-40% of AVT cases, alongside other factors like PNH and autoimmune disorders.
Conclusions:
- Abdominal vein thrombosis is a complex disorder often driven by multiple risk factors, necessitating prompt anticoagulant therapy.
- Life-long anticoagulation is recommended for Budd-Chiari syndrome patients, while treatment for portal vein thrombosis should be individualized based on risk factors and bleeding potential.
- Further research into optimal treatment duration is needed due to the high risk of both recurrence and bleeding in AVT patients.
Related Concept Videos
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Veins of the Abdomen and Pelvis
The inferior vena cava is fed by numerous smaller veins. The lumbar veins, for instance, drain the posterior abdominal wall, emptying both directly into the inferior vena cava and into the...
Varicose Veins I: Introduction

